OpenHealthTech / AISeries A
MediScan AI
AI diagnostic tool helping radiologists detect early-stage cancers with 99.2% accuracy.
Funding Progress
$720,000
raised of $1,200,000 target
60%
funded
Deal Summary
MediScan AI is developing FDA-cleared artificial intelligence software that assists radiologists in detecting early-stage cancers from medical imaging.
The Problem
Radiologists review hundreds of scans daily, leading to fatigue and missed diagnoses. Early detection of cancer dramatically improves patient outcomes.
Our Solution
Our AI acts as a "second pair of eyes," highlighting areas of concern and reducing false negatives by up to 40%.
Clinical Validation
- 99.2% sensitivity in breast cancer detection
- 97.8% sensitivity in lung nodule detection
- Validated in peer-reviewed studies
- FDA 510(k) clearance pending
Traction
- Deployed in 15 radiology practices
- 500,000+ scans analyzed
- $3.2M ARR with 95% retention
- LOIs from 3 hospital networks
Use of Funds
- 35% FDA clearance process
- 30% Clinical validation studies
- 25% Sales & Marketing
- 10% Operations
Investment Details
- Status
- Open
- Min. Ticket
- $50K
- Round Type
- Priced Round
- Lead Investor
- Health Ventures
- Amount Raised
- $720K
- Target
- $1.2M
- Funded
- 60%
For accredited investors only. Not investment advice.